Guerbet
Market Cap
€450.6m
Last Updated
2020/06/05 20:47 UTC
Data Sources
Company Financials +
Executive Summary
Guerbet SA engages in the research, development, production, and sale of contrast media products, delivery systems, medical devices, and related solutions worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Adequate balance sheet average dividend payer.
Similar Companies
Share Price & News
How has Guerbet's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GBT's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
2.7%
GBT
-11.5%
FR Medical Equipment
8.7%
FR Market
1 Year Return
-25.6%
GBT
42.8%
FR Medical Equipment
-2.4%
FR Market
Return vs Industry: GBT underperformed the French Medical Equipment industry which returned 47.4% over the past year.
Return vs Market: GBT underperformed the French Market which returned -3.8% over the past year.
Shareholder returns
| GBT | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.7% | -11.5% | 8.7% |
| 30 Day | 24.9% | -1.9% | 15.9% |
| 90 Day | 16.2% | 35.6% | 1.3% |
| 1 Year | -25.6%-25.6% | 42.8%42.8% | -0.7%-2.4% |
| 3 Year | -55.4%-56.8% | 43.9%42.1% | 11.2%2.2% |
| 5 Year | -5.1%-10.0% | 144.9%139.2% | 31.1%14.3% |
Price Volatility Vs. Market
How volatile is Guerbet's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Read This Before Buying Guerbet SA (EPA:GBT) For Its Dividend3 weeks ago | Simply Wall St
Declining Stock and Solid Fundamentals: Is The Market Wrong About Guerbet SA (EPA:GBT)?1 month ago | Simply Wall St
What Kind Of Investor Owns Most Of Guerbet SA (EPA:GBT)?Valuation
Is Guerbet undervalued compared to its fair value and its price relative to the market?
12.11x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: GBT (€35.9) is trading above our estimate of fair value (€20.97)
Significantly Below Fair Value: GBT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: GBT is good value based on its PE Ratio (12.1x) compared to the Medical Equipment industry average (47.3x).
PE vs Market: GBT is good value based on its PE Ratio (12.1x) compared to the French market (15.1x).
Price to Earnings Growth Ratio
PEG Ratio: GBT is poor value based on its PEG Ratio (11.7x)
Price to Book Ratio
PB vs Industry: GBT is good value based on its PB Ratio (1.2x) compared to the FR Medical Equipment industry average (2.6x).
Next Steps
Future Growth
How is Guerbet forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
1.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GBT's forecast earnings growth (1% per year) is above the savings rate (0.6%).
Earnings vs Market: GBT's earnings (1% per year) are forecast to grow slower than the French market (13.6% per year).
High Growth Earnings: GBT's earnings are forecast to grow, but not significantly.
Revenue vs Market: GBT's revenue is expected to decline over the next 3 years (-0.1% per year).
High Growth Revenue: GBT's revenue is forecast to decline over the next 3 years (-0.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GBT's Return on Equity is forecast to be low in 3 years time (9.3%).
Next Steps
Past Performance
How has Guerbet performed over the past 5 years?
7.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GBT has high quality earnings.
Growing Profit Margin: GBT's current net profit margins (4.6%) are lower than last year (5.9%).
Past Earnings Growth Analysis
Earnings Trend: GBT's earnings have grown by 7.9% per year over the past 5 years.
Accelerating Growth: GBT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GBT had negative earnings growth (-20.3%) over the past year, making it difficult to compare to the Medical Equipment industry average (-1.8%).
Return on Equity
High ROE: GBT's Return on Equity (9.6%) is considered low.
Next Steps
Financial Health
How is Guerbet's financial position?
Financial Position Analysis
Short Term Liabilities: GBT's short term assets (€515.2M) exceed its short term liabilities (€215.9M).
Long Term Liabilities: GBT's short term assets (€515.2M) exceed its long term liabilities (€403.7M).
Debt to Equity History and Analysis
Debt Level: GBT's debt to equity ratio (93%) is considered high.
Reducing Debt: GBT's debt to equity ratio has increased from 30% to 93% over the past 5 years.
Debt Coverage: GBT's debt is well covered by operating cash flow (36.3%).
Interest Coverage: GBT's interest payments on its debt are well covered by EBIT (7x coverage).
Balance Sheet
Next Steps
Dividend
What is Guerbet's current dividend yield, its reliability and sustainability?
1.95%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: GBT's dividend (1.95%) is higher than the bottom 25% of dividend payers in the French market (1.65%).
High Dividend: GBT's dividend (1.95%) is low compared to the top 25% of dividend payers in the French market (4.82%).
Stability and Growth of Payments
Stable Dividend: GBT's dividend payments have been volatile in the past 10 years.
Growing Dividend: GBT's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (23.6%), GBT's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: GBT's dividends in 3 years are forecast to be well covered by earnings (23.1% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.2yrs
Average management tenure
CEO
David Hale (50yo)
0.42
Tenure
Mr. David Hale has been Chief Executive Officer of Guerbet SA since January 1, 2020. Mr. Hale served as Chief Commercial Officer of Guerbet SA since 2019 until January 1, 2020 and served as its Chief Comme ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Pharmaceutical Officer & Deputy CEO | 4.17yrs | €236.95k | no data | |
| Chief Executive Officer | 0.42yr | no data | no data | |
| Chief Financial Officer | 1.17yrs | no data | no data | |
| Vice President of Purchasing & Member of Management Board | no data | no data | no data | |
| Vice President of Communications & Image | no data | no data | no data | |
| VP of European Operations & Member of Management Board | no data | no data | no data | |
| Member of Management Board | no data | no data | no data | |
| Chief Information Officer & Member of Management Board | no data | no data | no data | |
| Vice President of Human Resources | 0.42yr | no data | no data | |
| Chief Digital Officer and VP of Contrast Injection Systems R&D | 2.75yrs | no data | no data |
1.2yrs
Average Tenure
50yo
Average Age
Experienced Management: GBT's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non-Independent Director | 8.92yrs | €24.00k | no data | |
| Independent Director | 3.08yrs | €25.50k | no data | |
| Honorary Chairman | no data | €18.96k | 54.87% €247.3m | |
| Independent Chairwoman of the Board | 6.75yrs | €124.13k | no data | |
| Non-Independent Director | 7.08yrs | €27.00k | no data | |
| Non-Independent Director | 6.08yrs | €26.00k | no data | |
| Independent Director | 6.08yrs | €37.50k | no data | |
| Non-Independent Director | 5.08yrs | €23.00k | no data | |
| Non-Independent Director | 4.08yrs | €24.00k | no data | |
| Non-Independent Director | 3.08yrs | €22.50k | no data |
6.1yrs
Average Tenure
58yo
Average Age
Experienced Board: GBT's board of directors are considered experienced (6.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Guerbet SA's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Guerbet SA
- Ticker: GBT
- Exchange: ENXTPA
- Founded: 1926
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: €450.633m
- Shares outstanding: 12.55m
- Website: https://www.guerbet.com
Number of Employees
Location
- Guerbet SA
- 15, rue des Vanesses
- Zone Paris Nord II
- Villepinte
- Ile-de-France
- 93420
- France
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GUER.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jan 1992 |
| GBT | ENXTPA (Euronext Paris) | Yes | Ordinary Shares | FR | EUR | Jan 1992 |
| 0ELV | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Jan 1992 |
| 4G8 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jan 1992 |
| GBTP | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Jan 1992 |
| GBTNV | ENXTPA (Euronext Paris) | EUR1 (RFD 01/01/2020) | FR | EUR | Jan 2020 |
Biography
Guerbet SA engages in the research, development, production, and sale of contrast media products, delivery systems, medical devices, and related solutions worldwide. Its products for the CT and Cath Lab examinations include Optiray, a low osmolar contrast medium; Xenetix, a low-osmolar iodinated agent; Telebrix, a high osmolar contrast medium; Conray and MD high osmolar contrast medium products; and high osmolar contrast medium, an ionic low osmolar contrast medium agent. The company’s products for the magnetic resonance imaging (MRI) examinations comprise Dotarem, a non-specific gadolinium-based contrast medium; Artirem products; and Optimark, a contrast medium. In addition, it provides products for interventional imaging, including Lipiodol ethyl esters of iodinated fatty acids of poppy seed oil; Vectorio, a classic transarterial chemoembolization mixing and injection system; and Patent Blue V, an injectable medium. Further, the company offers delivery systems and services comprising injectors; consumables for various types of injectors; and Contrast&Care, a patient data management software. The company distributes its products directly, as well as through distributors and license-holders primarily to hospitals, clinics, radiology centers, purchasing pools, and wholesalers. Guerbet SA was founded in 1926 and is headquartered in Villepinte, France.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/05 20:47 |
| End of Day Share Price | 2020/06/05 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.